N6-methyladenosine (m6A) is the most abundant epigenetic modification in eukaryotic mRNAs and is essential for multiple RNA processing events during mammalian development and disease control. Here we show that conditional knockout of the m6A methyltransferase Mettl3 in bone marrow mesenchymal stem cells (MSCs) induces pathological features of osteoporosis in mice. Mettl3 loss-of-function results in impaired bone formation, incompetent osteogenic differentiation potential and increased marrow adiposity. Moreover, Mettl3 overexpression in MSCs protects the mice from estrogen deficiency-induced osteoporosis. Mechanistically, we identify PTH (parathyroid hormone)/Pth1r (parathyroid hormone receptor-1) signaling axis as an important downstream pathway for m6A regulation in MSCs. Knockout of Mettl3 reduces the translation efficiency of MSCs lineage allocator Pth1r, and disrupts the PTH-induced osteogenic and adipogenic responses in vivo. Our results demonstrate the pathological outcomes of m6A mis-regulation in MSCs and unveil novel epitranscriptomic mechanism in skeletal health and diseases.
Bone marrow mesenchymal stem cells (MSCs) are the common progenitors for osteoblasts and marrow adipocytes. The reciprocal balance between osteogenic and adipogenic differentiation of MSCs is under tightly spatiotemporal controls to safeguard skeletal health1,2,3. Aged-related osteoporosis is featured with low bone mass and excessive accumulation of adipose tissue in bone marrow milieu1,2,3. Under aging or other pathological stimuli such as hormone disorders, the bone marrow MSCs undergo preferential shift of differentiation towards adipocytes, resulting in the increase in marrow adiposity and progressive bone loss1,4,5. These alterations in bone micro-architecture lead to the increased skeletal fragility and susceptibility to fracture. However, the explicit mechanisms under which the lineage allocation of MSCs favors adipogenic to osteogenic lineage remain unclear.
N6-methyladenosine (m6A) is the most prevalent post-transcriptional internal mRNA modification that regulates the fine-tuning of a variety of biological processes6,7,8. In mammals, m6A is catalyzed by the methyltransferase complex consisting of an enzymatic subunit METTL3, a substrate recognition subunit METTL14 and a regulatory subunit WTAP9,10,11, and it can be erased by demethylases FTO and ALKBH512,13. At molecular level, m6A marks are dynamically installed and removed from their regulated transcripts to adjust RNA metabolisms, including alternative splicing, RNA stability, and translation, in response to multiple signaling cues during normal cellular processes or under stress or diseases14,15,16,17,18,19. Alterations in expressions of m6A methylated transcripts subsequently affect the cellular function, identity and stemness of their residing cells20,21,22,23,24, determining cell fate in a context-dependent manner. Recent in vivo studies made great breakthroughs in deciphering the intriguing involvement of m6A in mammalian development. Aberrant m6A levels upon Mettl3 and/or Mettl14 deficiency attenuated cell cycle progression, and disrupted the proper lineage commitment and differentiation of functional stem cells, resulting in retarded neurogenesis, immune defects, and infertility25,26,27,28. Given the strong correlation of m6A with health and diseases, we focus on exploring the potential involvement of m6A in bone homeostasis, about which little was known.
By generating conditional knockout and knock-in mutant mice, we unveil a crucial effect of m6A functioning in modulating MSCs differentiation, and discover PTH/Pth1r signaling axis as an important m6A downstream mechanism pathway. Our findings provide a new insight in the pivotal regulatory role of m6A in skeletal health and diseases.
Conditional deletion of Mettl3 in MSCs leads to low bone mass and high marrow adiposity
To study the potential role of Mettl3 in bone marrow MSCs lineage allocation and bone diseases, we first examined the expression of Mettl3 in mouse bone tissues. Immunostaining showed that Mettl3 is prevalently expressed in the bone cells and bone marrow of mice, but absent in chondrocytes of the growth plate zone (Supplementary Fig. 1). Since genomic Mettl3 knockout is embryonic lethal20, we generated Mettl3 flox (Mettl3fl/+) mice using CRISPR/Cas9 technique (Supplementary Fig. 2a), and then bred Mettl3fl/+ mice with Prx1-Cre transgenic mice to obtain conditional homozygous Mettl3 knockout mice, Prx1-Cre;Mettl3fl/fl mice, as well as heterozygous Mettl3 knockout mice, Prx1-Cre;Mettl3fl/+ mice (Supplementary Fig. 2b,c). Prx1-Cre;Mettl3fl/fl mice were viable, though with a lower survival rate (Supplementary Fig. 2d), and exhibited a sex bias towards maleness (about 4.5:1), in consistent with previous studies17,29. They had smaller size, lighter weight and retarded growth features compared to their Mettl3fl/fl control littermates at 4 weeks of age. Immunostaining of femur paraffin sections and western blot analysis proved the deletion of Mettl3 was successful, which subsequently reduced the m6A level in MSCs (Supplementary Fig. 2e-g).
Micro-computed tomography (μCT) analysis of trabecular bone of the distal femur metaphysis revealed that bone mineral density (BMD) and bone volume/tissue volume ratio (BV/TV) were significantly reduced in Prx1-Cre;Mettl3fl/fl and Prx1-Cre;Mettl3fl/+ male mice compared to their Mettl3fl/fl littermates (Fig. 1a, b). In addition, Mettl3 deletion also diminished the trabecular number (Tb.N), trabecular thickness (Tb.Th) and midshaft cortical thickness (Ct.Th), while increasing the trabecular separation (Tb.Sp) (Fig. 1b). Von Kossa staining of the undecalcified sections further confirmed the low bone mass phenotype of Prx1-Cre;Mettl3fl/fl mice (Fig. 1c). Moreover, the Mettl3 conditional knockout mice had slower mineral apposition rate (MAR) and bone formation rate (BFR), with also less osteoblast number (N.Ob/B.Pm) (Fig. 1e), suggesting that deletion of Mettl3 in MSCs contributed to the impaired bone formation in mice. We also observed a more active osteoclast state in Prx1-Cre;Mettl3fl/fl mice (Fig. 1d, e), supporting a faster bone tissue breakdown occurring in the Mettl3 conditional knockout mice. Mettl3 knockout only led to a slightly yet not significantly shortened growth plate and hypertrophic zones (Supplementary Fig. 3).
Interestingly, we observed that the loss of bone mass is associated with apparently increased bone marrow adipose tissue (MAT) accumulation in the Prx1-Cre;Mettl3fl/fl mice (Fig. 1f). Both the number and the density of marrow adipocytes were elevated in Prx1-Cre;Mettl3fl/fl mice compared to their Mettl3fl/fl controls (Fig. 1g). Overall, the skeletal manifestations of Mettl3 conditional knockout mice resemble the pathological phenotypes of osteoporosis, implying a lineage allocation disorder in MSCs with low m6A methylation level.
Loss of Mettl3 in MSCs leads to compromised osteogenic potential and increased adipogenic differentiation
Next, we isolated MSCs from Mettl3fl/fl and Prx1-Cre;Mettl3fl/fl mice to verify their osteogenic and adipogenic potentials in vitro. The incompetent osteogenic differentiation ability of Mettl3 deleted MSCs was evidenced by weaker alkaline phosphatase staining (ALP) activity and less calcium mineralization (Fig. 2a), and the downregulated expression of osteogenic markers, including Runx2, Sp7, Alp, and Bglap (Fig. 2b). On the contrary, the increased intensity of oil red O staining (Fig. 2c) and significantly elevated expression of adipogenic factors, including Pparγ, Cebpα, Adipoq, Plin1, and CD36 (Fig. 2d), demonstrated the enhanced adipogenic potential of Prx1-Cre;Mettl3fl/fl MSCs.
Deletion of Mettl3 in Lepr + MSCs results in bone impairment and marrow fat accumulation
We next sought to examine whether Mettl3 has comparable importance in a later stage of bone formation. To this end, we used Lepr-Cre line, which mainly targets at MSCs that majorly form bone tissues in adult bone marrow30,31. Lepr-Cre;Mettl3fl/fl mice recapitulated osteogenic block and adipogenic promotion seen in Prx1-Cre;Mettl3fl/fl mice. Deletion of Mettl3 in Lepr+ MSCs led to less trabecular bone in distal femoral, with a decrease in the number and thickness of trabeculae, as presented by lower BMD, BV/TV, Tb.N, and Tb.Th (Fig. 3a, b). Histological examination revealed an increased abundance of adipose tissue in bone marrow milieu of Lepr-Cre;Mettl3fl/fl mice in contrast to their Mettl3fl/fl littermates (Fig. 3c, d). Quantitative analysis of fat cells showed that both the fat cell number and density of the mutants increased more than doubled that of the controls (Fig. 3e).
Overexpression of Mettl3 prevents estrogen deficiency-induced osteoporosis
Considering the pathologic effect of Mettl3 deletion in triggering osteoporosis, we questioned whether Mettl3 overexpression is capable to enhance skeletal health or prevent bone disorders. To this end, we generated the Prx1-Cre driven Mettl3-tdTomato knock-in mice (Prx1-Cre;Mettl3KI/KI) to conditionally overexpress Mettl3 in MSCs (Supplementary Fig. 4a, b). Prx1-Cre;Mettl3KI/KI mice were viable and born at an expected Mendelian ratio. To study the potential protective role of Mettl3 overexpression in osteoporosis, 9-week-old Prx1-Cre;Mettl3KI/KI female mice and their control littermates were subjected to ovariectomy (OVX), a classic model to induce the postmenopausal osteoporosis32, in which the estrogen deprivation upon postmenopause gave rise to imbalanced bone remodeling and increased marrow fat deposition33. Although Prx1-Cre;Mettl3KI/KI mice did not exhibit significant change of bone mass in normal state, we observed a less decrease of trabecular bone density and bone volume in Mettl3 knock-in mice after OVX, compared to their controls (Fig. 4a, b). The decline in Tb.N and Tb.Th, as well as the increase in Tb.Sp were less obvious when Mettl3 was overexpressed (Fig. 4b). In addition, Mettl3 overexpression elevated osteoblast numbers in mice following OVX without affecting the osteoclast activity (Fig. 4c-e). H&E staining and histomorphology analysis revealed an excessive accumulation of marrow adipocytes in ovariectomized control mice whilst the increase was minor in the ovariectomized Prx1-Cre;Mettl3KI/KI mice (Fig. 4f, g).
m6A regulates the translation of parathyroid hormone receptor-1
To dissect the underlying mechanism of Mettl3 in regulation of MSCs fate and bone formation, we performed the m6A MeRIP-Seq to identify the critical m6A targets in MSCs (Supplementary Data 1). As shown in Supplementary Figure 5a-c, the “GGAC” sequence motif is enriched in the m6A sites identified in MSCs (Supplementary Fig. 5a), majority of the m6A sites are located in the CDS and the 3′UTR regions, with a small subset of peaks located in the 5′UTR and intron regions (Supplementary Fig. 5b). Metagene analysis revealed that the m6A sites were predominantly localized near the translation stop codons (Supplementary Fig. 5c). Furthermore, we found that Pth1r, a critical regulator of lineage allocation in MSCs and osteoblast precursors34,35,36, has high enriched and specific m6A peak near its translation stop codon (Fig. 5a, b).
Next, we carried out RNA sequencing (RNA-seq) to examine transcriptome profiles in MSCs isolated from Prx1-Cre;Mettl3fl/fl mice and Mettl3fl/fl controls, and confirmed the down-regulated expression of osteogenic marker genes, such as Dlx5, Sp7, Alpl, and Bglap, whereas upregulated expression of markers favoring adipocytic differentiation, including Pparg, Plin1, and Fabp4 (Fig. 5c). PTH1R is a key receptor of PTH and a parathyroid hormone-related protein (PTHrP) analog, abaloparatide, both are FDA-approved anabolic drugs for the treatment of osteoporosis37,38, and is indispensable for PTH’s function in modulating bone homeostasis39,40. To confirm that m6A modulates Pth1r, we preceded our RNA-seq data to gene set enrichment analysis (GSEA) using a published list of PTH-regulated genes41. We found that Mettl3-deficient MSCs underwent a global down-regulation of PTH-regulated gene expression (Fig. 5d), implying PTH/Pth1r signaling axis as a potential mechanism for Mettl3-mediated m6A methylation on MSCs fate.
Both RNA-seq and quantitative RT-PCR showed that the mRNA expression of Pth1r was hardly affected by Mettl3 deletion (Fig. 5e), whereas the Pth1r protein synthesis was inhibited upon Mettl3 deficiency as evidenced by western blot and decreased translation efficiency (Fig. 5f, g), suggesting that m6A methylation affected Pth1r expression at translation level. We subsequently performed sucrose gradient centrifugation to resolve polysome fractions of Mettl3 knockout and control MSCs, and used RT-PCR to examine the distribution of endogenous Pth1r mRNA in different ribosome fractions. Our data revealed that the relative distribution of Pth1r mRNA was shifted from the polysome fractions to the sub-polysome fractions in Mettl3 knockout cells, indicating that Mettl3 depletion results in the decreased translation efficiency of Pth1r mRNA (Fig. 5h, i).
m6A is essential for PTH function
Since Pth1r protein synthesis was hampered by Mettl3 depletion, we next examined physiological functions of PTH/Pth1r axis upon Mettl3 deficiency. Cyclic AMP-dependent protein kinase A (PKA) and extracellular signal-regulated kinases (ERK) pathways are important downstream pathways that mediate the intracellular signals and physiological responses during the anabolic effect of PTH42,43. Loss of Mettl3 attenuated the PTH-induced cAMP accumulation of Prx1-Cre;Mettl3fl/fl MSCs (Fig. 6a) and consequently inhibited the downstream phosphorylation of cAMP response element-binding protein (CREB) (Fig. 6b). Meanwhile, despite having the same basal level of ERK1/2 as the control MSCs, mutant MSCs failed to activate the ERK1/2 pathway after PTH treatment (Fig. 6b).
To investigate the potential role of Mettl3 in PTH-mediated bone remodeling in vivo, we performed intermittent PTH (1-34) injection to 3-month-old Mettl3fl/fl and Prx1-Cre;Mettl3fl/+ female mice to compare their responses to PTH treatment. In contrast with the sharp growth of trabecular bone mass in Mettl3fl/fl controls, there were only slight changes in the BMD, BV/TV, Tb.N and Tb.Sp in the Prx1-Cre;Mettl3fl/+ mice (Fig. 6c, d). Furthermore, Prx1-Cre;Mettl3fl/+ mice failed to undergo an effective increase in bone remodeling after PTH treatment (Fig. 6e–g), confirming that Mettl3 knockout blunted PTH-induced osteogenic effects. Besides a marked enrichment in osteogenesis, PTH also inhibits adipocytic differentiation to promote bone formation35,44. In our experiment, PTH injection significantly reduced MAT accumulation in Mettl3fl/fl mice whilst hardly reversing the high marrow adiposity in Prx1-Cre;Mettl3fl/+ mice (Fig. 6h, i), consolidating our findings that m6A affects both osteogenic and adipogenic differentiation of MSCs by regulating PTH/Pth1r signaling axis.
Overexpression of Pth1r partially rescues the proper lineage commitment of Mettl3-deficient MSCs
Next, we transduced adenoviral constructs overexpressing Pth1r (Ad-Pth1r), or gfp (Ad-gfp) as a control, into Prx1-Cre;Mettl3fl/fl MSCs. Ad-Pth1r successfully restored the protein level of Pth1r in Prx1-Cre;Mettl3fl/fl MSCs (Fig. 7a), and significantly improved the ALP activity and calcium nodule formation (Fig. 7b, c). Furthermore, Pth1r overexpression ameliorated the increased intensity of oil red O staining arising from m6A reduction (Fig. 7e). qRT-PCR analysis also revealed an up-regulation of osteogenic markers along with a down-regulation of adipogenic markers after Pth1r transduction (Fig. 7d, f). These data demonstrate that Pth1r overexpression is able to partially rescue the proper lineage commitment of Mettl3-deficient MSCs.
Mettl3-mediated m6A modification in eukaryotic RNA has a broad functional influence on stabilizing homeostasis, while any perturbation in m6A levels can result in malfunction or diseases. Recent studies have consecutively revealed a strong and intricate relation of m6A modification with stem cell regulation. Mis-regulated m6A level disrupted the timely controlled embryonic stem cell differentiation20,21, impaired the normal generation and differentiation of hematopoietic stem cells23,24 as well as inhibiting functional development of neurogenesis, spermatogenesis, and T cell homeostasis25,26,27,28,45. Using different temporal MSCs markers, Prx1 and Lepr, we generated two genetic murine models to conditionally knockout Mettl3 from early limb bud mesenchyme and adult bone marrow, respectively. We showed that deletion of Mettl3 in bone marrow MSCs disrupts cell fate in mice and results in osteoporosis pathological phenotypes such as decreased bone mass with incompetent osteogenic potential, and increased marrow adiposity with enhanced adipogenic potential, uncovering an efficient and specific regulation of m6A on MSCs. Furthermore, Mettl3 gain-of-function prevents estrogen deficiency-induced postmenopausal osteoporosis, establishing the indispensability of Mettl3 in defining bone marrow MSC’s fate and thereby ensuring skeletal health.
Accumulating evidences have pointed out the regulatory role of m6A in translation. In cooperation with m6A readers, m6A facilitates translation initiation, and responds to selective mRNA translation under heat shock stress14,16,46,47,48. Alterations in translation efficiency of m6A marked transcripts affected normal hematopoiesis23,24 and mammalian spermatogenesis28,49. Here we discover that m6A is essential for Pth1r translation. Loss of Mettl3 caused strong shift of Pth1r mRNA from the polysome fractions to the sub-polysome fractions, therefore slowing down the protein synthesis of Pth1r and further blocking the downstream signaling pathways of Pth1r responsive to PTH treatment.
Intermittent PTH treatment promotes bone formation, which is achieved by increasing osteoblasts number, delaying osteoblast apoptosis, activating bone-lining cells and reducing marrow fat34,42,44. PTH1R is a direct signaling mediator of PTH in promoting osteoblastic lineage of MSCs while aberrant PTH1R expression can lead to MAT accumulation as a consequence of preferential adipogenic differentiation34,35,50. Mettl3 knockout reduced the global methylation level of m6A in mice and significantly impaired Pth1r function. The persistence in high marrow adiposity and the poorly elevated bone mass in m6A deficient mice following intermittent PTH(1-34) injection supported a blunt response to PTH anabolic effect. Our subsequent finding that overexpression of Pth1r could largely reverse skewed MSCs differentiation towards adipocytes and improve osteogenesis further confirmed PTH/Pth1r signaling pathway as a novel mechanism whereby Mettl3-mediated m6A modification controls the lineage allocation of MSCs.
PTH also stimulates osteoclast formation and activity by increasing the receptor activator of nuclear factor κ-B ligand (RANKL)/osteoprotegerin (OPG) ratio through its receptor51,52,53. Although the protein synthesis of Pth1r was largely compromised upon Mettl3 ablation in our study, we found that the number of osteoclasts was rather elevated. One explanation for this increase in osteoclasts, we presume, is that Mettl3 has another relevant target in bone cells besides Pth1r, since our overexpression of Pth1r has only achieved a partial rescue. Another possible explanation is that the adipogenic favored differentiation of MSCs upon Pth1r malfunction promotes osteoclast activity. Fan et al. demonstrated in their recent study that bone marrow adipocytes are the source of RANKL in the absence of PTH1R signaling34. Similar to their finding, our TRAP staining showed that osteoclasts in Mettl3 mutant mice were located very near to the large adipocytes (Fig. 1d). Therefore, we speculated that the excessive accumulated marrow adipose tissue in Mettl3 conditional knockout mice may also account for the increase of osteoclast number.
Of note, unlike the severe chondrodysplasia in Prx1-Cre;PTH1Rfl/fl mice reported by Fan et al.54, we observed only slight yet not significant growth plate cellular architecture changes in Prx1-Cre;Mettl3fl/fl mice. Our finding that Mettl3 does not express in growth plate chondrocytes, thus may not participate in chondrogenesis, can be an explanation for this discrepancy in growth plate phenotype. The minute difference in hypertrophic zone between Prx1-Cre;Mettl3fl/fl mice and their controls might due to an indirect effect of Pth1r impairment in Mettl3-depleted osteoblasts, which further affects endochondral vascularization in the growth plate55.
In summary, we demonstrate that reduced epigenetic modification of m6A in bone marrow MSCs from an early phase inhibits Pth1r translation in mammals and blocks their anabolic responses to PTH during bone accrual. These functional defects tilt the delicate MSC differentiation balance toward adipogenic lineage, causing severe bone loss and excessive MAT accumulation. Our data enrich the evidence of m6A in modulating stem cell differentiation, and uncover the functional link between mis-regulated m6A modification and bone pathological disorders, therefore may shed light on the development of new therapeutic strategies for osteoporosis.
Generation of conditional Mettl3 knockout and knock-in mice
For conditional knockout, Mettl3fl/+ mice with C57BL6/J background were generated using CRISPR-Cas9 systems56,57. Briefly, the exon 2 and exon 3 of Mettl3 is the target of interest in generation of conditional knockout floxed Mettl3 allele. With the help of a CRISPR design tool (http://crispr.mit.edu), sgRNAs were designed to recognize a region either upstream or downstream of the target, and then were screened for on-target activity using a Universal CRISPR Activity Assay (UCATM, Biocytogen Inc, Beijing). Donor vectors structured with the Lox P flanked exon 2 and exon 3 was mixed with Cas9 mRNA and sgRNAs and co-injected into the cytoplasm of one-cell stage fertilized C57BL6/J eggs. The injected zygotes were then transferred into oviducts of Kunming pesudopregnant females to obtain F0 mice. Tail genomic DNA PCR and sequencing were performed to identify F0 mice with expected genotype, which were afterwards crossed with C57BL6/J mice to establish germline-transmitted F1 founders. Both PCR genotyping and southern blot were applied to ensure the correct genotype of generated Mettl3fl/+ mice.
For conditional knock-in, CRISPR-Cas9 techniques were also performed. The targeting vector consisting of a loxP flanked stop codon regulatory element and a downstream Mettl3 coding sequence (CDS) was inserted into wild type Rosa26 allele to obtain the targeted conditional Mettl3 knock-in allele. We designed a tdTomato sequence at the downstream of Mettl3 CDS to facilitate our verification of knock-in efficiency later in the research. The targeted allele was then reconstructed into a plasmid under the mediation of Cas9/sgRNAs. After the co-injection of the reconstructed plasmid into fertilized C57BL6/J eggs, PCR genotyping and southern blot were executed to obtain desirable F1 mice that were recombined with targeted Mettl3 knock-in alleles.
Prx1-Cre and Lepr-Cre transgenic mice were purchased from The Jackson Laboratory. We crossed male Prx1-Cre or Lepr-Cre mice with Mettl3fl/+ mice to obtain Prx1-Cre;Mettl3fl/+ mice and Lepr-Cre;Mettl3fl/+ mice as heterozygous conditional Mettl3 knockout. By mating Prx1-Cre;Mettl3fl/+ or Lepr-Cre;Mettl3fl/+ male mice with Mettl3fl/+ female mice, we obtained Prx1-Cre;Mettl3fl/fl mice and Lepr-Cre;Mettl3fl/fl mice as homozygous conditional Mettl3 knockout mice. The same mating strategy was used in the generation of conditional Mettl3 knock-in mice.
The genotype of transgenic mice was identified by PCR analyses of genomic DNA extracted from mouse tails. Primers for floxed Mettl3 knockout allele genotyping were forward (5′-TCCCTGGGAAACATAATCACATCC-3′) and reverse (5′-CTTCTCCTCCTCTCAAATGATACAAT-3′). Primers for floxed Mettl3 knock-in allele genotyping were forward (5′-AGTCGCTCTGAGTTGTTATCAG-3′), wild-type band reverse (5′-TGAGCATGTCTTTAATCTACCTCGATG-3′), mutant band reverse (5′- AGTCCCTATTGGCGTTACTATGG-3′). Primers for Cre transgene genotyping were wild-type band forward (5′-CCATCTGCCACCAGCCAG-3′), wild-type band reverse (5′-TCGCCATCTTCCAGCAGG-3′), mutant band forward (5′-ACTGGGATCTTCGAACTCTTTGGAC-3′), and mutant band reverse (5′-GATGTTGGGGCACTGCTCATTCACC-3′). All the mice were bred and maintained under specific-pathogen-free conditions. All studies performed were approved by the Subcommittee on Research and Animal Care (SRAC) of Sichuan University.
LC-MS/MS analysis of m6A level
The integrity and quantity of each total RNA samples extracted from primary MSCs was examined using agarose gel electrophoresis and Nanodrop™ instrument. mRNA was isolated from total RNA using NEBNext® Poly(A) mRNA Magnetic Isolation Module (For next generation sequencing using). Purified mRNA was quantified using NanoDrop ND-1000. mRNA was hydrolyzed to single nucleosides and then nucleosides were dephosphorylated by enzyme mix. Pretreated nucleosides solution was deproteinized using Satorius 10,000-Da MWCO spin filter.
Analysis of nucleoside mixtures was performed on Agilent 6460 QQQ mass spectrometer with an Agilent 1290 HPLC system. Multi reaction monitoring (MRM) mode was performed because of its high selectivity and sensitivity attained working with parent-to-product ion transitions. LC-MS/MS data was acquired using Agilent Qualitative Analysis software. MRM peaks of each modified nucleoside were extracted and normalized to peak areas of normal adenosine in each samples. Samples were run in duplicate, and m6A/A ratios were calculated.
μCT and histomorphometric analyses
The harvested bone tissues were fixed in 4% polyoxymethylene for 2 days and then stored in 70% ethanol at 4 °C before being processed. μCT analysis was performed according to recent guidelines58 using a μCT 80 microCT system (Scanco Medical, Bassersdorf, Switzerland) with a spatial resolution of 8 μm (55 kV, 114 mA, 500 ms integration time). For the analysis of cortical bone regeneration, the volume of interest (VOI) was defined as a cylindrical area covering the initial bone defect. Bone volume (BV/TV) was calculated within the delimited VOI.
Processing of undecalcified bone specimens and cancellous bone histomorphometry were performed as described59,60. Followed by microCT scanning, femurs were dehydrated and embedded in methylmethacrylate. Five‐µm‐thick sections were prepared using a Leica RM2235 microtome and were stained by the von Kossa/nuclear fast red method. Histomorphometric measurements in the distal end of femurs were made using OsteoMeasure software (OsteoMetrics, Decatur, GA).
The dissected femurs were fixed in 4% polyoxymethylene for 2 days and decalcified in 10% EDTA for 2 weeks before sectioning (5 μm). Slides were subjected to sodium citrate buffer at 99 °C for 20 min for antigen retrieval and then incubated with rabbit anti-METTL3/MT-A70 (1:200, Bethyl, Cat No: A301-567A), or rabbit polyclonal anti-FABP4 (1:200, Abcam, Cat No: ab13979).
Nine-week-old female conditional Mettl3 knock-in mice and littermate controls were selected for ovariectomy and randomly assigned to OVX or sham group. Ovaries were surgically removed on both sides after anesthesia61. In short, small dorsal incisions below the bottom of the rib cage were made to penetrate the skin and muscles respectively. After locating the ovary, we exposed the oviduct and ligated it before the removal of the ovary. For sham group, ovaries were replaced back into the peritoneal cavity directly after their locating. Finally, we sutured the wound and bred the operated mice in sham and OVX group for another 5 weeks before sacrifice.
We isolated primary MSCs by flushing the bone marrow of tibiae and femurs. The cells were then cultured in α-MEM (Hyclone) supplemented with 10% fetal bovine serum (Gibco),100 units/ml penicillin (Gibco) and 100 μg/ml streptomycin (Gibco), at 37 °C with an atmosphere of 5% CO2 and 95% humidity. For osteogenic induction, MSCs were seeded in six-well plates and treated with osteogenic medium containing 50 μg/ml ascorbic acid, 5 mM β-glycerophosphate, and 100 nM dexamethasone (all from Sigma). For adipogenic induction, MSCs were seeded in six-well plates and treated with adipogenic medium containing 0.5 μM isobutylmethylxanthin (Sigma), 10 μg/ml insulin (Sigma), and 1 μM dexamethasone (Sigma).
ALP, alizarin red staining, and oil red O staining
For ALP staining, cells were fixed after 10 days induction of osteogenic differentiation with 4% polyoxymethylene for 15 min and incubated with 0.1 M Tris buffer (pH 9.3) containing 0.25% naphthol AS-BI phosphate (Sigma) and 0.75% Fast Blue BB (Sigma). Quantitative ALP activity was performed with a commercial kit according to the manufacturer’s protocol (Cell Biolab, San Diego, CA). The optical density was determined by a spectrophotometer (Thermo Fisher Scientific) at 450 nm.
For alizarin red staining (ARS) staining, cells were fixed after 10 days induction of osteogenic differentiation with 4% polyoxymethylene for 15 min and stained with 1% Alizarin red S (pH 4.2, Sigma-Aldrich) for 5 min. Mineralized matrix stained with alizarin red were destained with 10% cetylpyridinium chloride in 10 mM sodium phosphate (pH 7.0), and the calcium concentration was determined by a spectrophotometer (Thermo Fisher Scientific) at 562 nm using a standard calcium curve in the same solution62,63.
For oil red O staining, after 2–3 weeks of adipogenic induction, cells were subjected to oil red O staining (Sigma) according to the manufacturer’s protocols. The staining was then dissolved with isopropanol and quantified by a spectrophotometer (Thermo Fisher Scientific) at 450 nm, as described previously34.
Total RNA of cultured cells was extracted using Trizol (Invitrogen) according to manufacturer’s instruction. cDNA was prepared using PrimeScript RT reagent Kit with gDNA Eraser (Takara). The RNA concentration was measured with a NanoDrop 2000 (Thermo Fisher Scientific). qRT-PCR was performed using SYBR Premix Ex Taq II (Takara) in CFX96 Real-Time System (Bio-Rad). Relative gene expression was normalized by Gapdh for osteogenic differentiation and 36B4 for adipogenic differentiation using a 2−ΔΔCt method. The primers are listed in Supplementary Table 1.
Cells were lysed in RIPA buffer (Pierce, Rockford, IL) on ice. For PTH treatment group, cells were given 100 nM human recombinant PTH (1-34) (Bachem, Torrance, CA, USA) at 37 °C for 30 min prior to sampling. The samples were heated at 95 ℃ for 5 min in sample buffer containing 2% SDS and 1% 2-mercaptoethanol, separated on 10% SDS–polyacrylamide gels, and transferred to PVDF membranes by a wet transfer apparatus (Bio-Rad). The membranes were blotted with 5% BSA for 1 h and then incubated overnight with rabbit METTL3 polyclonal antibody (1:1000, Proteintech, Cat No: 15073-1-AP), PTH1R antibody (1:1000, Assay Biotechnology, Cat No: G220), p44/42 MAPK (Erk1/2) rabbit mAb (1:1000, Cell signaling, Cat No: 4695), phospho-p44/42 MAPK (Erk1/2) rabbit mAb (1:2000, Cell signaling, Cat No: 4370), CREB rabbit mAb (1:1000, Cell signaling, Cat No: 9197), phospho-CREB rabbit mAb (1:1000, Cell signaling, 9198), α-tubulin rabbit polyclonal antibody (1:2000, Beyotime, Cat No: AF0001), followed by incubation with a goat anti-rabbit IgG secondary antibody HRP conjugated (1:5000, Signaling antibody, Cat No: L3012-2). The antibody-antigen complexes were visualized with Immobilon reagents (Millipore). The uncropped gel images are shown in Supplementary Fig. 6.
m6A MeRIP-Seq (methylated RNA immunoprecipatation and sequencing)
The MSC m6A MeRIP-Seq and data analysis were performed as previously described64,65. Briefly, Trizol reagent was used for the isolation of total RNA from MSC, and then the PolyATtract mRNA Isolation System IV (Promega Z5310) was used to enrich mRNA from MSC total RNA sample. Two μg of the purified mRNA was fragmentized into about 100 nt length with ZnCl2 buffer at 94 °C for 5 min. The mRNA fragments were purified with Oligo Clean & ConcentratorTM (Zymoresearch D4061) and then subjected to immunoprecipitation with α-m6A antibody (1:100, Synaptic Systems, Cat No: 202003). After extensive wash, the methylated fragments were eluted by competition using free N6-Methyladenosine (Santa Cruz Biotechnology, sc-215524) and then used for library construction with the TruSeq Stranded mRNA Sample Prep Kits (Illumina RS-122-2101). The input and m6A MeRIP libraries were sequenced with Illumina NextSeq 500 with high output kit. The sequence reads mapping, peak calling and visualization, metagene analysis of m6A distribution, motif search and gene ontology analysis were performed as previously described65.
RNA-seq and gene set enrichment analysis
Total RNAs from MSCs of Prx1-Cre;Mettl3fl/fl mice and their control littermates were extracted by Trizol reagent and purified using poly-T oligo-attached magnetic beads. Sequencing libraries were generated using NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (NEB, USA) following manufacturer’s recommendations, and were then subjected to Illumina HiSeq 2500. We used FastQC (v0.11.5) and FASTX toolkit (0.0.13) to control the quality of RNA-seq data and mapped them to Mus musculus reference genomes using HISAT2 (v.2.0.4). Ballgown software (v.3.4.0) was performed to identify differentially expressed genes and transcripts. Genes were considered significantly differentially expressed if showing ≥2.0 fold change and P value < 0.05.
For GSEA, PTH-regulated gene list was obtained from a published study41. GSEA were performed with GSEA software (http://www.broad.mit.edu/GSEA) as previously described66. In short, we first imported our gene list of interest into the software and examined whether this given gene set showed statistically significant, concordant differences between two biological states (for example, phenotypes). P values were computed using a bootstrap distribution created by resampling gene sets of the same cardinality.
Polysome fractionation and RT-PCR
Cells were washed with ice old PBS twice and then PBS containing 100 μg/ml Cycloheximide was added to the cell culture dishes to stop translation. Cells were scraped and lyzed with cell extraction buffer to collect the cytoplasmic extracts, which were loaded onto the top of 11 ml 10–50% sucrose gradient tube. The sucrose gradient tubes were centrifuged at 222,000 × g with SW41Ti rotor for 2 h and 30 min at 4 °C. Then the ribosome fractions were collected using the ISCO gradient fractionators, with measurement of absorbance at 254 nm. RNA samples were isolated from different fractions using Trizol and reverse transcription and PCR were performed as previously described to determine the relative distribution of Pth1r mRNA in different ribosome fractions65.
Cells were cultured in six-well plates and stimulated with vehicle or 100 nM human recombinant PTH (1-34) (Bachem, Torrance, CA, USA) at 37 °C for 15 min67. We then carried out the cAMP assay using the cAMP Biotrak Enzymeimmunoassay (EIA) System (GE Healthcare Bio-Science Corp., Piscataway, NJ, USA) and followed the manufacturer’ s instruction.
Intermittent PTH (1-34) injection
Subcutaneous daily injection of 80 μg/kg of human recombinant PTH (1-34) (Bachem, Torrance, CA, USA) was given to 12-week-old female Prx1-Cre;Mettl3fl/+ and control mice for 4 weeks. An equal volume of sterile saline was given to animals in the vehicle group. The assignment of Prx1-Cre;Mettl3fl/+ and control mice into PTH or vehicle group was randomized.
Adenoviruses encoding mouse Pth1r gene and/or green fluorescent protein (GFP) were obtained from Cyagen. Primary MSCs isolated from bone marrow of tibiae and femurs were infected with Ad-Pth1r or Ad-gfp for 12 h at 37 °C with an atmosphere of 5% CO2 and 95% humidity.
All data were expressed as mean ± s.e.m. Statistical differences were analyzed by unpaired two-tailed Student’s t test for comparison between two groups, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, and two-way ANOVA followed by Bonferroni post test for comparison between sham and OVX groups, as well as vehicle and PTH treatment groups. A P value <0.05 was considered to be statistically significant.
All Seq data have been deposited into NCBI database with the identifier GSE114933.
Rosen, C. J. & Bouxsein, M. L. Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheum. 2, 35–43 (2006).
Devlin, M. J. & Rosen, C. J. The bone–fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol. 3, 141–147 (2015).
Kawai, M., Devlin, M. J. & Rosen, C. J. Fat targets for skeletal health. Nat. Rev. Rheumatol. 5, 365–372 (2009).
Rosen, C. J., Ackertbicknell, C., Rodriguez, J. P. & Pino, A. M. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit. Rev. Eukar. Gene 19, 109–124 (2009).
Scheller, E. L. & Rosen, C. J. What’s the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann. NY Acad. Sci. 1311, 14–30 (2014).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).
Yue, Y., Liu, J. & He, C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Gene. Dev. 29, 1343–1355 (2015).
Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505, 117–120 (2014).
Wang, P., Doxtader, K. A. & Nam, Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63, 306–317 (2016).
Wang, X. et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature 534, 575–578 (2016).
Ping, X. L. et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 24, 177–189 (2014).
Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011).
Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49, 18–29 (2013).
Zhou, J. et al. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature 526, 591–594 (2015).
Dominissini, D. et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485, 201–206 (2012).
Wang, X. et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388–1399 (2015).
Lence, T. et al. m(6)A modulates neuronal functions and sex determination in Drosophila. Nature 540, 242–247 (2016).
Zhang, S. et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 31, 591–606 (2017).
Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature 552, 126–131 (2017).
Geula, S. et al. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science 347, 1002–1006 (2015).
Batista, P. J. et al. m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell 15, 707–719 (2014).
Zhang, C. et al. m6A modulates haematopoietic stem and progenitor cell specification. Nature 549, 273–276 (2017).
Weng, H. et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell 22, 191–205 (2018).
Vu, L. P. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23, 1369–1376 (2017).
Yoon, K. J. et al. Temporal control of mammalian cortical neurogenesis by m6A methylation. Cell 171, 877–889 (2017).
Li, H. B. et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature 548, 338–342 (2017).
Xu, K. et al. Mettl3-mediated m6A regulates spermatogonial differentiation and meiosis initiation. Cell Res. 27, 1100–1114 (2017).
Lin, Z. et al. Mettl3-/Mettl14-mediated mRNA N6-methyladenosine modulates murine spermatogenesis. Cell Res. 27, 1216–1230 (2017).
Haussmann, I. U. et al. m(6)A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination. Nature 540, 301–304 (2016).
Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154–168 (2014).
Yue, R., Zhou, B. O., Shimada, I. S., Zhao, Z. & Morrison, S. J. Leptin receptor promotes adipogenesis and reduces osteogenesis by regulating mesenchymal stromal cells in adult bone marrow. Cell Stem Cell 18, 782–796 (2016).
Kalu, D. N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15, 175–191 (1991).
Lewiecki, E. M. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat. Rev. Rheumatol. 7, 631–638 (2011).
Fan, Y. et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell. Metab. 25, 661–672 (2017).
Balani, D. H., Ono, N. & Kronenberg, H. M. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J. Clin. Invest. 127, 3327–3338 (2017).
Wanida, O., Naoko, S., Shigeki, N., Noriaki, O. & Kronenberg, H. M. Parathyroid hormone receptor signalling in osterix-expressing mesenchymal progenitors is essential for tooth root formation. Nat. Commun. 7, 11277 (2016).
Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Miller, P. D. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722–733 (2016).
Jüppner, H. et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254, 1024–1026 (1991).
Abousamra, A. B. et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracell. Proc. Natl Acad. Sci. USA 89, 2732–2736 (1992).
Qin, L. et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J. Biol. Chem. 278, 19723–19731 (2003).
Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434–1446 (2007).
Gesty-Palmer, D. et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856–10864 (2006).
Rickard, D. J. et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39, 1361–1372 (2006).
Wang, Y. et al. N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. Nat. Neurosci. 21, 195–206 (2018).
Shi, H. et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. 27, 315–328 (2017).
Li, A. et al. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res. 27, 444–447 (2017).
Yang, Y. et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 27, 626–641 (2017).
Hsu, P. J. et al. Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 27, 1115–1127 (2017).
Calvi, L. M. et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107, 277–286 (2001).
Silva, B. C., Costa, A. G., Cusano, N. E., Kousteni, S. & Bilezikian, J. P. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J. Endocrinol. Invest. 34, 801–810 (2011).
Silva, B. C. & Bilezikian, J. P. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr. Opin. Pharmacol. 22, 41–50 (2015).
Wein, M. N. & Kronenberg, H. M. Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb. Perspect. Med. 8, a031237 (2018).
Fan, Y. et al. Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis. FASEB J. 30, 428 (2016).
Qiu, T. et al. PTH receptor signaling in osteoblasts regulates endochondral vascularization in maintenance of postnatal growth plate. J. Bone Miner. Res. 30, 309–317 (2015).
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
Zhang, F. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468–1486 (2010).
Yuan, Q. et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. J. Bone Miner. Res. 29, 693–704 (2014).
Liu, W. et al. GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat. Commun. 7, 12794 (2016).
Guo, Y. et al. Estrogen deficiency leads to further bone loss in the mandible of CKD mice. PLoS ONE 11, e0148804 (2016).
Zhou, C. C. et al. AFF1 and AFF4 differentially regulate the osteogenic differentiation of human MSCs. Bone Res. 5, 207–216 (2017).
Guo, Y. C. et al. Ubiquitin‐specific protease USP34 controls osteogenic differentiation and bone formation by regulating BMP2 signaling. EMBO J. e99398 (2018).
Dominissini, D., Moshitch-Moshkovitz, S., Salmon-Divon, M., Amariglio, N. & Rechavi, G. Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on immunocapturing and massively parallel sequencing. Nat. Protoc. 8, 176–189 (2013).
Lin, S., Choe, J., Du, P., Triboulet, R. & Gregory, R. I. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62, 335–345 (2016).
Bo, Y. et al. KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β-catenin signalling. Nat. Commun. 8, 15146 (2017).
Yuan, Q. et al. FGF‐23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J. Bone Miner. Res. 26, 2026–2035 (2011).
This work was supported by grants from the National Natural Science Foundation of China (NSFC, 81722014, 81571001, 81772999, 81500354, and 81621062), Sichuan Province Science and Technology Innovation Team Program (2017TD0016), State Key Laboratory of Oral Diseases (SKLOD201704), and The National Key R&D Program of China during the 13th Five-Year Plan (2016YFC1102700). Quan Yuan is the lead contact for this article.
The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wu, Y., Xie, L., Wang, M. et al. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun 9, 4772 (2018). https://doi.org/10.1038/s41467-018-06898-4
A Ten-N6-Methyladenosine (m6A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma
Frontiers in Oncology (2021)
Cell & Bioscience (2021)
Regulatory Role of the RNA N6-Methyladenosine Modification in Immunoregulatory Cells and Immune-Related Bone Homeostasis Associated With Rheumatoid Arthritis
Frontiers in Cell and Developmental Biology (2021)
Stem Cells and Development (2021)
Aging Cell (2021)